Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 7Myeloid 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Blast Crisis 1

Interventions

fludarabine 63Cyclophosphamide 63venetoclax 57Azacitidine 52fludarabine phosphate 50Specimen Handling 44Whole-Body Irradiation 40ruxolitinib 37Mycophenolic Acid 37Tacrolimus 35Melphalan 32Busulfan 32Biopsy 32Cytarabine 31Stem Cell Transplantation 27Decitabine 27Granulocyte Colony-Stimulating Factor 21asciminib 19decitabine and cedazuridine drug combination 18Sirolimus 18Peripheral Blood Stem Cell Transplantation 18Injections 18Thiotepa 17Filgrastim 17nilotinib 15X-Rays 14Methotrexate 14Cyclosporine 14Imatinib Mesylate 13Magnetic Resonance Spectroscopy 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
midostaurin × Myeloid × 1 year × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡